162.55
price down icon1.13%   -1.85
after-market Dopo l'orario di chiusura: 162.55
loading
Precedente Chiudi:
$164.40
Aprire:
$161.24
Volume 24 ore:
2.13M
Relative Volume:
1.31
Capitalizzazione di mercato:
$24.59B
Reddito:
$4.39B
Utile/perdita netta:
$853.00M
Rapporto P/E:
29.50
EPS:
5.5097
Flusso di cassa netto:
$556.00M
1 W Prestazione:
+11.93%
1M Prestazione:
+19.72%
6M Prestazione:
+27.44%
1 anno Prestazione:
+100.46%
Intervallo 1D:
Value
$159.48
$163.88
Intervallo di 1 settimana:
Value
$142.94
$165.97
Portata 52W:
Value
$78.79
$165.97

Illumina Inc Stock (ILMN) Company Profile

Name
Nome
Illumina Inc
Name
Telefono
(858) 202-4500
Name
Indirizzo
5200 ILLUMINA WAY, SAN DIEGO, CA
Name
Dipendente
8,650
Name
Cinguettio
@illumina
Name
Prossima data di guadagno
2026-04-30
Name
Ultimi documenti SEC
Name
ILMN's Discussions on Twitter

Compare ILMN vs TMO, DHR, IDXX, A, WAT

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
ILMN icon
ILMN
Illumina Inc
162.55 24.87B 4.39B 853.00M 556.00M 5.5097
TMO icon
TMO
Thermo Fisher Scientific Inc
482.08 183.60B 45.20B 6.87B 6.75B 18.19
DHR icon
DHR
Danaher Corp
176.11 127.31B 24.78B 3.68B 5.29B 5.1743
IDXX icon
IDXX
Idexx Laboratories Inc
550.82 44.71B 4.45B 1.10B 1.06B 13.59
A icon
A
Agilent Technologies Inc
135.05 38.38B 7.23B 1.41B 1.09B 4.979
WAT icon
WAT
Waters Corp
371.93 37.13B 3.77B 449.25M 240.68M 7.8556

Illumina Inc Stock (ILMN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-08-12 Downgrade Daiwa Securities Outperform → Neutral
2025-07-11 Downgrade Scotiabank Sector Outperform → Sector Perform
2025-03-04 Reiterato Citigroup Neutral
2025-02-28 Downgrade HSBC Securities Buy → Hold
2025-02-10 Downgrade Barclays Equal Weight → Underweight
2025-02-07 Downgrade TD Cowen Buy → Hold
2024-12-11 Downgrade Citigroup Buy → Neutral
2024-11-12 Ripresa Morgan Stanley Equal-Weight
2024-10-17 Aggiornamento HSBC Securities Hold → Buy
2024-08-28 Aggiornamento Argus Hold → Buy
2024-08-16 Aggiornamento Daiwa Securities Neutral → Buy
2024-08-14 Aggiornamento Barclays Underweight → Equal Weight
2024-08-14 Aggiornamento TD Cowen Hold → Buy
2024-07-10 Aggiornamento Citigroup Neutral → Buy
2024-06-03 Ripresa Jefferies Hold
2024-01-16 Downgrade HSBC Securities Buy → Hold
2024-01-04 Downgrade TD Cowen Outperform → Market Perform
2023-12-18 Aggiornamento Scotiabank Sector Perform → Sector Outperform
2023-12-15 Aggiornamento Bernstein Underperform → Mkt Perform
2023-12-14 Iniziato Guggenheim Buy
2023-12-14 Iniziato Stephens Overweight
2023-12-13 Iniziato Wolfe Research Outperform
2023-12-12 Downgrade BofA Securities Neutral → Underperform
2023-12-11 Aggiornamento Citigroup Sell → Neutral
2023-11-10 Downgrade Canaccord Genuity Buy → Hold
2023-09-28 Iniziato Bernstein Underperform
2023-07-05 Ripresa JP Morgan Neutral
2023-01-25 Downgrade Argus Buy → Hold
2023-01-05 Iniziato Scotiabank Sector Perform
2022-12-12 Downgrade Citigroup Neutral → Sell
2022-12-07 Iniziato RBC Capital Mkts Outperform
2022-10-04 Aggiornamento SVB Leerink Mkt Perform → Outperform
2022-09-28 Aggiornamento Evercore ISI In-line → Outperform
2022-08-25 Iniziato Credit Suisse Neutral
2022-07-13 Downgrade Barclays Equal Weight → Underweight
2022-01-18 Aggiornamento Stifel Hold → Buy
2022-01-11 Aggiornamento Barclays Underweight → Equal Weight
2022-01-07 Aggiornamento BofA Securities Underperform → Neutral
2022-01-06 Ripresa Morgan Stanley Equal-Weight
2022-01-06 Ripresa Piper Sandler Overweight
2021-10-15 Ripresa Cowen Outperform
2021-08-19 Downgrade SVB Leerink Outperform → Mkt Perform
2021-06-01 Aggiornamento Evercore ISI Underperform → In-line
2021-03-31 Downgrade Atlantic Equities Overweight → Neutral
2021-03-31 Aggiornamento Canaccord Genuity Hold → Buy
2021-03-03 Iniziato Barclays Underweight
2020-12-22 Aggiornamento Piper Sandler Neutral → Overweight
2020-12-17 Aggiornamento BTIG Research Neutral → Buy
2020-10-13 Downgrade Guggenheim Buy → Neutral
2020-09-30 Iniziato Atlantic Equities Overweight
2020-09-29 Downgrade Wolfe Research Outperform → Peer Perform
2020-09-22 Downgrade Stifel Buy → Hold
2020-09-22 Downgrade UBS Buy → Neutral
2020-09-21 Aggiornamento Guggenheim Neutral → Buy
2020-09-21 Downgrade JP Morgan Overweight → Neutral
2020-09-09 Iniziato Morgan Stanley Equal-Weight
2020-08-07 Downgrade Evercore ISI In-line → Underperform
2020-08-07 Downgrade Piper Sandler Overweight → Neutral
2020-07-07 Downgrade Guggenheim Buy → Neutral
2020-04-24 Downgrade Citigroup Buy → Neutral
2020-04-21 Downgrade Robert W. Baird Outperform → Neutral
2020-01-08 Iniziato Wells Fargo Underweight
2020-01-07 Iniziato Citigroup Buy
2020-01-02 Downgrade Evercore ISI Outperform → In-line
2019-11-15 Iniziato Stifel Buy
2019-10-25 Iniziato Guggenheim Buy
Mostra tutto

Illumina Inc Borsa (ILMN) Ultime notizie

pulisher
12:19 PM

Insider Sell: Scott Davies Sells Shares of Illumina Inc (ILMN) - GuruFocus

12:19 PM
pulisher
Jun 01, 2026

Why (ILMN) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Jun 01, 2026
pulisher
Jun 01, 2026

Corvex funds tied to Illumina (ILMN) log 669,596-share stock sale - Stock Titan

Jun 01, 2026
pulisher
Jun 01, 2026

Guggenheim raises Illumina stock price target on clinical market strength - Investing.com UK

Jun 01, 2026
pulisher
Jun 01, 2026

Illumina VP, chief accounting officer sells $305,150 in ILMN stock - Investing.com

Jun 01, 2026
pulisher
Jun 01, 2026

Illumina (ILMN) legal chief sells 615 shares in open market trade - Stock Titan

Jun 01, 2026
pulisher
Jun 01, 2026

Illumina Inc. stock (US4523271090): New oncology research workflows and MRD solution highlight innov - AD HOC NEWS

Jun 01, 2026
pulisher
Jun 01, 2026

Illumina (ILMN) chief accounting officer sells 2,000 company shares in open market - Stock Titan

Jun 01, 2026
pulisher
Jun 01, 2026

Hunting for hidden clues in the human genome’s “dark regions” - Illumina

Jun 01, 2026
pulisher
Jun 01, 2026

Integrated DNA Technologies (DHR) Partners with Illumina for Enh - GuruFocus

Jun 01, 2026
pulisher
Jun 01, 2026

IDT partners with Illumina on oncology research workflow - Investing.com

Jun 01, 2026
pulisher
Jun 01, 2026

Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights - Eagle-Tribune

Jun 01, 2026
pulisher
Jun 01, 2026

Integrated DNA Technologies and Illumina, Inc. Announce Strategic Collaboration for End-to-End Oncology Research Workflows Optimized on Illumina Software - marketscreener.com

Jun 01, 2026
pulisher
Jun 01, 2026

Guggenheim Maintains Illumina(ILMN.US) With Buy Rating, Raises Target Price to $180 - Moomoo

Jun 01, 2026
pulisher
Jun 01, 2026

Guggenheim raises Illumina stock price target on clinical market strength By Investing.com - Investing.com Australia

Jun 01, 2026
pulisher
Jun 01, 2026

Illumina, Inc. (ILMN) Stock Analysis: Understanding the Growth Potential Amidst a Robust Market Cap - DirectorsTalk Interviews

Jun 01, 2026
pulisher
May 31, 2026

Illumina Inc. stock (US4523271090): shares track Nasdaq ahead of next catalysts - AD HOC NEWS

May 31, 2026
pulisher
May 30, 2026

Illumina Oncology Launches Put Product Depth Against Rapid Share Price Gains - Yahoo Finance Singapore

May 30, 2026
pulisher
May 30, 2026

Illumina Inc. stock (US4523271090): insider share sale and new MRD kit draw investor focus - AD HOC NEWS

May 30, 2026
pulisher
May 29, 2026

Why Illumina (ILMN) is a top momentum stock for the long term - MSN

May 29, 2026
pulisher
May 29, 2026

Illumina Ducks DNA Sequence Rival's Antitrust Suit, For Now - Law360

May 29, 2026
pulisher
May 29, 2026

Corvex Management LP sells multiple ILMN blocks (ILMN) in May 2026 - Stock Titan

May 29, 2026
pulisher
May 29, 2026

Illumina, Inc. Hits New 52-Week High of $158.78, Up 48.7% - Markets Mojo

May 29, 2026
pulisher
May 29, 2026

Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch

May 29, 2026
pulisher
May 29, 2026

lllumina Beats Rival’s DNA-Sequencing Tool Monopolization Claims - Bloomberg Law News

May 29, 2026
pulisher
May 29, 2026

Illumina, Inc. Hits Day High with Strong 5.68% Intraday Surge - Markets Mojo

May 29, 2026
pulisher
May 29, 2026

Illumina (NASDAQ: ILMN) director sold 1,500 shares under 10b5-1 plan - Stock Titan

May 29, 2026
pulisher
May 29, 2026

[144] ILLUMINA, INC. SEC Filing - Stock Titan

May 29, 2026
pulisher
May 29, 2026

Illumina (ILMN) director Keith Meister updates 3.5M indirect share position - Stock Titan

May 29, 2026
pulisher
May 29, 2026

Illumina Inc. stock (US4523271090): shares near 12-month high after new automation launch - AD HOC NEWS

May 29, 2026
pulisher
May 29, 2026

Illumina launches new sequencing tech for molecular residual disease research - MSN

May 29, 2026
pulisher
May 29, 2026

Illumina and SPT Labtech on fire with new collaboration - Business Weekly

May 29, 2026
pulisher
May 29, 2026

Assessing Illumina (ILMN) Valuation After Its New MRD Research Solution Expands Oncology Offering - Sahm

May 29, 2026
pulisher
May 28, 2026

Illumina Inc stock (US4523271090): New MRD research launch and fresh 52-week high draw focus to valu - AD HOC NEWS

May 28, 2026
pulisher
May 28, 2026

Illumina (ILMN) Form 144: Brokered notice to sell 1,500 shares - Stock Titan

May 28, 2026
pulisher
May 28, 2026

Illumina stock hits 52-week high at 155.6 USD By Investing.com - Investing.com Nigeria

May 28, 2026
pulisher
May 28, 2026

Frances Arnold proposes sale of 5,000 ILMN shares (ILMN) - Stock Titan

May 28, 2026
pulisher
May 28, 2026

Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research - Illumina

May 28, 2026
pulisher
May 28, 2026

Illumina's new fireflyGO robot targets faster cancer lab workflows - Stock Titan

May 28, 2026
pulisher
May 28, 2026

Illumina, Inc. Introduces Distributed Whole-Genome Sequencing Solution For Highly Sensitive MRD Research - marketscreener.com

May 28, 2026
pulisher
May 28, 2026

Illumina stock hits 52-week high at 155.6 USD - Investing.com

May 28, 2026
pulisher
May 28, 2026

Illumina launches whole-genome sequencing kit for cancer research By Investing.com - Investing.com Australia

May 28, 2026
pulisher
May 28, 2026

Illumina launches whole-genome sequencing kit for cancer research - Investing.com

May 28, 2026
pulisher
May 28, 2026

Illumina cancer research workflow spots tiny traces of disease in 5 days - Stock Titan

May 28, 2026
pulisher
May 27, 2026

Illumina Shareholders Back Board, Auditor and Executive Pay - The Globe and Mail

May 27, 2026
pulisher
May 27, 2026

Is Illumina Inc (ILMN) Overvalued After 3.4% Rally? GF Value Say - GuruFocus

May 27, 2026
pulisher
May 27, 2026

Illumina, Inc. Files Form 8-K Announcing Annual Meeting Results and Company Information (May 2026) - Minichart

May 27, 2026
pulisher
May 26, 2026

Illumina (ILMN) shareholders back board slate, auditor and pay at 2026 meeting - Stock Titan

May 26, 2026
pulisher
May 26, 2026

Illumina (ILMN) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance

May 26, 2026
pulisher
May 26, 2026

Action challenging Commission’s jurisdiction over Grail’s acquisition of Illumina, published in OJ - EU Law Live

May 26, 2026
pulisher
May 25, 2026

Illumina Multiomics Summit India highlights potential of integrated omics - BioSpectrum India

May 25, 2026

Illumina Inc Azioni (ILMN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
MTD MTD
$1,170.00
price down icon 1.15%
DGX DGX
$193.16
price up icon 0.50%
IQV IQV
$180.64
price down icon 3.31%
$212.73
price down icon 2.78%
WAT WAT
$371.93
price down icon 1.65%
Capitalizzazione:     |  Volume (24 ore):